Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment

Reuters

10/16

Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment

Overview

Pulmatrix Q3 2025 revenue decreased to $0, primarily due to winding down PUR1900 clinical trial
Company plans to divest iSPERSE technology amid proposed merger with Cullgen
Pulmatrix's cash position expected to fund operations into Q4 2026

Outlook

Pulmatrix plans to divest its iSPERSE™ technology as part of a merger
Company anticipates cash position sufficient to fund operations into Q4 2026
Pulmatrix did not provide specific financial guidance for future quarters

Result Drivers

MERGER FOCUS - Pulmatrix is advancing steps to complete the proposed merger with Cullgen, which includes divesting its iSPERSE™ technology and related clinical programs
REVENUE DECLINE - Revenue decreased to $0 due to the completion of the wind down of the PUR1900 Phase 2b clinical trial during 2024
COST REDUCTION - R&D and administrative costs fell due to winding down PUR1900 trial, disposal of leases and employee termination

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.24
Q3 Net Income		-$877,000
Q3 Income from Operations		-$866,000
Q3 Operating Expenses		$866,000

Press Release: ID:nPn2WNTq8a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2575745037"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575745037\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575745037?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-16 20:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575745037","market":"nz","top_or_hot":-1,"title":"Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment</title></head><body><p><span>Overview</span></p><ul><li><p>Pulmatrix Q3 2025 revenue decreased to $0, primarily due to winding down PUR1900 clinical trial</p></li><li><p>Company plans to divest iSPERSE technology amid proposed merger with Cullgen</p></li><li><p>Pulmatrix's cash position expected to fund operations into Q4 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Pulmatrix plans to divest its iSPERSE™ technology as part of a merger</p></li><li><p>Company anticipates cash position sufficient to fund operations into Q4 2026</p></li><li><p>Pulmatrix did not provide specific financial guidance for future quarters</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>MERGER FOCUS - Pulmatrix is advancing steps to complete the proposed merger with Cullgen, which includes divesting its iSPERSE™ technology and related clinical programs</p></li><li><p>REVENUE DECLINE - Revenue decreased to $0 due to the completion of the wind down of the PUR1900 Phase 2b clinical trial during 2024</p></li><li><p>COST REDUCTION - R&amp;D and administrative costs fell due to winding down PUR1900 trial, disposal of leases and employee termination</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.24</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$877,000</p></td><td></td></tr><tr><td><p>Q3 Income from Operations</p></td><td></td><td><p>-$866,000</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$866,000</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nPn2WNTq8a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-16 20:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment</title></head><body><p><span>Overview</span></p><ul><li><p>Pulmatrix Q3 2025 revenue decreased to $0, primarily due to winding down PUR1900 clinical trial</p></li><li><p>Company plans to divest iSPERSE technology amid proposed merger with Cullgen</p></li><li><p>Pulmatrix's cash position expected to fund operations into Q4 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Pulmatrix plans to divest its iSPERSE™ technology as part of a merger</p></li><li><p>Company anticipates cash position sufficient to fund operations into Q4 2026</p></li><li><p>Pulmatrix did not provide specific financial guidance for future quarters</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>MERGER FOCUS - Pulmatrix is advancing steps to complete the proposed merger with Cullgen, which includes divesting its iSPERSE™ technology and related clinical programs</p></li><li><p>REVENUE DECLINE - Revenue decreased to $0 due to the completion of the wind down of the PUR1900 Phase 2b clinical trial during 2024</p></li><li><p>COST REDUCTION - R&amp;D and administrative costs fell due to winding down PUR1900 trial, disposal of leases and employee termination</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.24</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$877,000</p></td><td></td></tr><tr><td><p>Q3 Income from Operations</p></td><td></td><td><p>-$866,000</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$866,000</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nPn2WNTq8a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL2N3VX0EB:1","article_id":"2575745037","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575745037","pubTimestamp":1760616971,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestmentOverviewPulmatrix Q3 2025 revenue decreased to $0, primarily due to winding down PUR1900 clinical trialCompany plans t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PULM":"Pulmatrix, Inc."},"translate_title":"随着试验结束，生物制药Pulmatrix第三季度收入降至0美元，计划资产剥离","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PULM":0.9},"content_text":"Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestmentOverviewPulmatrix Q3 2025 revenue decreased to $0, primarily due to winding down PUR1900 clinical trialCompany plans to divest iSPERSE technology amid proposed merger with CullgenPulmatrix's cash position expected to fund operations into Q4 2026OutlookPulmatrix plans to divest its iSPERSE™ technology as part of a mergerCompany anticipates cash position sufficient to fund operations into Q4 2026Pulmatrix did not provide specific financial guidance for future quartersResult DriversMERGER FOCUS - Pulmatrix is advancing steps to complete the proposed merger with Cullgen, which includes divesting its iSPERSE™ technology and related clinical programsREVENUE DECLINE - Revenue decreased to $0 due to the completion of the wind down of the PUR1900 Phase 2b clinical trial during 2024COST REDUCTION - R&D and administrative costs fell due to winding down PUR1900 trial, disposal of leases and employee terminationKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.24Q3 Net Income-$877,000Q3 Income from Operations-$866,000Q3 Operating Expenses$866,000Press Release: ID:nPn2WNTq8aFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}